Liver Steatosis and Bariatric Surgery

Jaime Ruiz-Tovar, MD, PhD (Editor)
Department of Bariatric Surgery, Centro de Excelencia para el Diagnostico y Tratamiento de la Obesidad (Valladolid-Spain, Professor of Surgery, Universidad Alfonso X, Madrid (Spain)
Department of Surgery, Universidad Autónoma de Madrid, Spain
Obesity Unit, Garcilaso Clinic, Madrid, Spain
Department of Surgery. Centro de Excelencia para el Estudio y Tratamiento de la Obesidad, Valladolid, Spain
Department of Surgery, University Hospital Rey Juan Carlos, Mostoles, Madrid, Spain

Lorea Zubiaga, MD, PhD (Editor)
Inserm U1190, Lille 2 University, Lille, France
Hospital General Universitario de Elche & Universidad Miguel Hernández de Elche, Elche-Alicante-Spain

Series: Surgery – Procedures, Complications, and Results
BISAC: MED085000

Clear

$160.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Liver steatosis or nonalcoholic fatty liver disease (NAFLD) is a progressive disorder characterized by the fat accumulation in the parenchyma of the liver. The progressive form of NAFLD called nonalcoholic steatohepatitis (NASH) is the advanced condition that shows different grades of fibrosis, which could progress to cirrhosis, hepatocellular carcinoma and liver-related morbidity and mortality.

Bariatric surgery gains attention as a potential treatment for liver steatosis because different studies revealed an improvement in 90% of cases of fatty liver after surgery. The improvement occurred within the first year and persisted up to five years. Pathogenic mechanisms that are involved in the evolution steatosis are intimately connected with insulin resistance, type 2 diabetes (T2D) and the metabolic syndrome. Bariatric surgery is a powerful treatment to ameliorate all these conditions.

The aim of this book is to update the actual evidence about liver steatosis, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in morbidly obese patients, the diagnostic methods and the evolution after the different techniques of bariatric surgery.
(Imprint: Nova Medicine and Health)

Preface

Chapter 1. Introduction to NAFLD and NASH: Etiopathogenesis
(Soledad García-Gómez-Heras, MD, PhD, Julio Paredes-González, Pathological Anatomy Technician, Raquel Franco-Rodríguez, Pathological Anatomy Technician, Human Histology and Pathology, Health Science Department, Rey Juan Carlos University, Madrid, Spain)

Chapter 2. Epidemiology and Relevance of NASH in Patients with Morbid Obesity
(Leire Zarain-Obrador, MD, and Manuel Duran-Poveda, MD, PhD, Department of Endocrine and Bariatric Surgery, King Juan Carlos University Hospital, Madrid, Spain, and others)

Chapter 3. Fatty Liver Development: Imbalance between Acquisition and Removal of Lipids
(Lorea Zubiaga, MD, PhD, Lille University, EGID, CHU Lille. Lille, France)

Chapter 4. Histopathology of NAFLD and NASH
(Soledad García-Gómez-Heras, MD, PhD, Human Histology and Pathology, Health Science Department. Rey Juan Carlos University, Madrid, Spain)

Chapter 5. Liver Biopsy as the "Gold Standard" in NASH Diagnosis
(Soledad García-Gómez-Heras, MD, PhD, Julio Paredes-González, Pathological Anatomy Technician, Raquel Franco-Rodríguez, Pathological Anatomy Technician, Human Histology and Pathology, Health Science Department. Rey Juan Carlos University, Madrid, Spain)

Chapter 6. Conventional Imaging Tests for the Evaluation of NASH
(Luis Tomás Ocaña Wilhelmi MD, PhD, Bruno Ramos Molina, PhD, Enrique Glückmann Maldonado, MD,
Surgery Department, University of Málaga, Málaga, Spain)

Chapter 7. MR Spectroscopy and Quantification of Intrahepatocitary Lipid Content
(Jaime Ruiz-Tovar, MD, PhD, and Carolina Llavero, Obesity Unit, Garcilaso Clinic, Madrid, Spain)

Chapter 8. Biochemical Markers
(Soledad García-Gómez-Heras, MD, PhD, Human Histology and Pathology, Health Science Department. Rey Juan Carlos University, Madrid, Spain)

Chapter 9. Evolution of Liver Steatosis after Sleeve Gastrectomy
(Ramiro Carbajal Nicho, MD, Andrei Sarmiento Alarcón, MD, Nestor Palacios Bran, and MD, Jorge Orrego Peche, MD, Metabolic and Bariatric Surgeon, Hospital Edgardo Rebagliati, Lima, Perú, and others)

Chapter 10. Liver Steatosis and Roux-en-Y Gastric Bypass (RYGB)
(Luciano Deluca, MD, Liliana Parasporo, MD, Patricio Cal, MD, and Ezequiel Fernández, MD, Programa de Cirugía Bariátrica, Hospital Churruca, Buenos Aires, Argentina, and others)

Chapter 11. Liver Steatosis Regression after One Anastomosis Gastric Bypass
(Luciano Antozzi, MD, Miguel Angel Carbajo MD, PhD, Priscila Antozzi, MD, Carlos Martin Esquivel, MD, PhD, Centro de Cirugías Especiales, Bahía Blanca, Argentina)

Chapter 12. SADI-S: Characteristics and Results of a Novel Bariatric Surgery Technique. The Role in NAFLD and NASH
(Esteban Martin-Antona, MD, Oscar Cano-Valderrama, MD, PhD, Ester Martin Garcia-Almenta, MD, PhD, Miguel Josa, MD, PhD, and Antonio J. Torres, MD, PhD, Department of Surgery, Hospital Clinico San Carlos, Madrid, Spain)

Chapter 13. Simultaneous Liver Transplantation and Bariatric Surgery
(David Calatayud, MD, PhD, Eva María Montalvá, MD, PhD, Javier Maupoey, MD, PhD, Andrea Boscá, MD, PhD, and Rafael López-Andújar, MD, PhD, Division of Hepatobiliopancreatic Surgery and Transplants. Department of Surgery, Hospital Universitari i Politècnic La Fe, Valencia, Spain)

Chapter 14. Non-Surgical Treatment of NASH: The Other Options
(Raúl Bernal Reyes, MD, and Daniel Bernal Serrano, MD, School of Medicine UNAM, México City, Mexico, and others)

Index

You have not viewed any product yet.